- AstraZeneca Plc (NASDAQ:AZN) posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD).
- NMOSD is an autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves.
- The data showed that Ultomiris significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD, compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.
- Data showed zero adjudicated relapses were observed among Ultomiris patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%). Additionally, 100% of patients receiving Ultomiris remained relapse-free at 48 weeks, compared to 63% of patients in the external placebo arm.
- The CHAMPION-NMOSD trial also met key secondary efficacy endpoints, including adjudicated on-trial annualized relapse rate and clinically important change from baseline in the ability to walk.
- Price Action: AZN shares are down 0.20% at $57.85 on the last check Thursday.
Alkermes’ Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
Alkermes plc (NASDAQ: ALKS)
